Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

608 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety and immunogenicity of a pichia pastoris-expressed bivalent human papillomavirus (types 16 and 18) L1 virus-like particle vaccine in healthy Chinese women aged 9-45 years: A randomized, double-blind, placebo-controlled phase 1 clinical trial.
Li J, Shi LW, Yu BW, Huang LR, Zhou LY, Shi L, Jiang ZW, Xia JL, Wang XY, Li RC, Yuan L, Li YP, Li CG. Li J, et al. Among authors: zhou ly. Vaccine. 2023 May 5;41(19):3141-3149. doi: 10.1016/j.vaccine.2023.04.009. Epub 2023 Apr 13. Vaccine. 2023. PMID: 37061370 Free article. Clinical Trial.
Development of recombinant COVID-19 vaccine based on CHO-produced, prefusion spike trimer and alum/CpG adjuvants.
Liu H, Zhou C, An J, Song Y, Yu P, Li J, Gu C, Hu D, Jiang Y, Zhang L, Huang C, Zhang C, Yang Y, Zhu Q, Wang D, Liu Y, Miao C, Cao X, Ding L, Zhu Y, Zhu H, Bao L, Zhou L, Yan H, Fan J, Xu J, Hu Z, Xie Y, Liu J, Liu G. Liu H, et al. Vaccine. 2021 Nov 26;39(48):7001-7011. doi: 10.1016/j.vaccine.2021.10.066. Epub 2021 Oct 30. Vaccine. 2021. PMID: 34750014 Free PMC article.
Safety and immunogenicity of a bivalent HPV16/18 vaccine in Chinese females.
Shi LW, Li J, Yu BW, Huang LR, Li K, Ji M, Zhou LY, Yuan L, Yang SY, Chen JJ, Wang L, Jiang ZW, Li RC, Li YP, Xia JL, Mo ZJ, Li CG. Shi LW, et al. Among authors: zhou ly. Hum Vaccin Immunother. 2023 Dec 31;19(1):2209001. doi: 10.1080/21645515.2023.2209001. Epub 2023 May 30. Hum Vaccin Immunother. 2023. PMID: 37249310 Free PMC article. Clinical Trial.
Safety, tolerability, and immunogenicity of a CpG/Alum adjuvanted SARS-CoV-2 recombinant protein vaccine (ZR202-CoV) in healthy adults: Preliminary report of a phase 1, randomized, double-blind, placebo-controlled, dose-escalation trial.
Feng GW, Wang ZF, He P, Lan QY, Ni L, Yang YZ, Wang CF, Cui TT, Huang LL, Yan YQ, Jiang ZW, Yang Q, Yu BW, Han X, Chen JJ, Yang SY, Yuan L, Zhou LY, Liu G, Li K, Huang Z, Zhao JC, Hu ZY, Xie ZQ. Feng GW, et al. Among authors: zhou ly. Hum Vaccin Immunother. 2023 Aug;19(2):2262635. doi: 10.1080/21645515.2023.2262635. Epub 2023 Oct 26. Hum Vaccin Immunother. 2023. PMID: 37881130 Free PMC article. Clinical Trial.
A potent, broadly protective vaccine against SARS-CoV-2 variants of concern.
Wang Z, An J, Liu K, Yu P, Fang X, Li J, Zhu H, Zhu Q, Huang C, Zhang C, Zhao B, Bao L, Song Y, Cao X, Hu D, Jiang Y, Shi L, Zhou L, Fan J, Guan W, Zhou C, Hu Z, Yuan Z, Liu J, Shan C, Liu G. Wang Z, et al. NPJ Vaccines. 2022 Nov 12;7(1):144. doi: 10.1038/s41541-022-00571-0. NPJ Vaccines. 2022. PMID: 36371432 Free PMC article.
608 results